Picture of Replimune logo

REPL Replimune Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual income statement for Replimune, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

2019
March 31st
2020
March 31st
2021
March 31st
2022
March 31st
2023
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Total Revenue00000
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses30.956.280.9118177
Operating Profit-30.9-56.2-80.9-118-177
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-30.8-52.6-80.9-118-174
Provision for Income Taxes
Net Income After Taxes-30.8-52.6-80.9-118-174
Net Income Before Extraordinary Items
Net Income-30.8-52.6-80.9-118-174
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-30.8-52.6-80.9-118-174
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.33-1.54-1.73-2.26-2.99
Dividends per Share